Kodiak Sciences soars as Zenkuda, tabirafusp-ted hit primary endpoints in phase III wet AMD trial — Live Feedhttps://www.live-feeds.com/feed/kodiak-sciences-soars-as-zenkuda-tabirafusp-ted-hit-primary-endpoints-in-phase-iii-wet-amd-trialContinuously updated, source-cited coverage. Kodiak Sciences stock surges after Phase III wet AMD trial successhttps://www.live-feeds.com/feed/kodiak-sciences-soars-as-zenkuda-tabirafusp-ted-hit-primary-endpoints-in-phase-iii-wet-amd-trialhttps://www.live-feeds.com/feed/kodiak-sciences-soars-as-zenkuda-tabirafusp-ted-hit-primary-endpoints-in-phase-iii-wet-amd-trial#u100638Mon, 05 Oct 2026 00:20:26 +0000Kodiak Sciences shares rose over 162% by midday Monday after two drug candidates, Zenkuda and tabirafusp-ted, met primary endpoints in the Phase III DAYBREAK trial for wet age-related macular degeneration. The therapies demonstrated statistical equivalence and non-inferiority to aflibercept. Zenkuda, also known as tarcocimab tedromer, showed vision gains and retinal drying with a p-value of 0.0007. Notably, 54% of patients in the trial reached a six-month dosing interval. The results have led to bullish analyst revisions and substantial insider buying, though some valuation risks persist.Why i